各种靶向药和化疗药物的说明书

老马兄很好，很好

$ f" S) i, Q7 d1 {
健择（吉西他滨）+顺铂+阿瓦斯汀
Gemzar +Cisplatin + Avastin
, v( E. k$ V5 |1 ohttp://annonc.oxfordjournals.org/content/21/9/1804.full
* g2 w& j3 e# U) lOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
: a6 ?5 r. D/ m( XResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
4 |4 X, X9 B! \0 F- D& v. D Cisplatin Gemzar Avastin.PDF (329.84 KB, 下载次数: 1056)

2013-3-13 13:39 上传

点击文件名下载附件

8 ]7 K- [( I* _% e9 H1 a  r华为网盘附件：
【华为网盘】ava.JPG
2 T" C' w, p' F+ k# s5 z

这个很实用，很好
4 b2 z( R& O6 b7 Y4 m谢谢

知识很全,谢谢老马提供

论坛里有用信息真多，努力学习中…
8 J2 w- z& s8 M, V' B( w
$ Z  E/ S" U/ G$ ~谢谢老马，谢谢大家！

有没有每个肿瘤的用药组合推荐啊？

收藏了谢谢老马。

此帖必火

老马整理的太好了~~感谢啊！